302 related articles for article (PubMed ID: 1744800)
1. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
Delahaye M; Hoogsteden HC; Van der Kwast TH
J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
[TBL] [Abstract][Full Text] [Related]
2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
3. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
4. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry.
Tickman RJ; Cohen C; Varma VA; Fekete PS; DeRose PB
Acta Cytol; 1990; 34(4):491-6. PubMed ID: 2197840
[TBL] [Abstract][Full Text] [Related]
5. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
O'Hara CJ; Corson JM; Pinkus GS; Stahel RA
Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835
[TBL] [Abstract][Full Text] [Related]
6. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
7. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
8. [Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1].
Daste G; Berthier F; Mauduyt MA; Soleilhavoup JP
Arch Anat Cytol Pathol; 1992; 40(4):183-9. PubMed ID: 1294046
[TBL] [Abstract][Full Text] [Related]
9. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic role of claudins in serous effusions.
Kleinberg L; Holth A; Fridman E; Schwartz I; Shih IeM; Davidson B
Am J Clin Pathol; 2007 Jun; 127(6):928-37. PubMed ID: 17509990
[TBL] [Abstract][Full Text] [Related]
11. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
12. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
13. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
14. Identification of carcinoma cells in ascitic and pleural fluid. Comparison of four panepithelial antigens with carcinoembryonic antigen.
Mezger J; Stötzer O; Schilli G; Bauer S; Wilmanns W
Acta Cytol; 1992; 36(1):75-81. PubMed ID: 1546516
[TBL] [Abstract][Full Text] [Related]
15. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
Zhu W; Michael CW
Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
Hecht JL; Pinkus JL; Pinkus GS
Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
[TBL] [Abstract][Full Text] [Related]
17. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
[TBL] [Abstract][Full Text] [Related]
18. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
19. Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study.
van der Kwast TH; Versnel MA; Delahaye M; de Jong A; Zondervan PE; Hoogsteden H
Acta Cytol; 1988; 32(2):169-74. PubMed ID: 3348058
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen.
Ernst CS; Atkinson B; Chianese D; Peters J; Perry M; Herlyn M; Koprowski H
Appl Pathol; 1986; 4(3):115-24. PubMed ID: 2885017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]